| Patents for C07D 211 - Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings (37,939) |
|---|
| 03/21/2002 | WO2002022580A1 Antibacterials mutilins |
| 03/21/2002 | WO2002022579A2 Antipsychotic sulfonamide-heterocycles, and methods of use thereof |
| 03/21/2002 | WO2002022572A2 Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| 03/21/2002 | WO2002022550A2 Chiral amino alcohols and process for preparation of same |
| 03/21/2002 | WO2002006255A3 Hydroxy-(piperidin-4-yl-methylamino)-alkyl beta-3 adrenergic receptor antagonists |
| 03/21/2002 | WO2001076599B1 Process of making racemic bupivacaine's enantiomers, levobupivacaine's pharmaceutical compositions, levobupivacaine's pharmaceutical compositions formulated on its free base form or its pharmaceutical acceptable salts and use of levobupivacaine's pharmaceutical compositions formulated on its free base form |
| 03/21/2002 | US20020035263 Novel arylpiperidine and aryl-1,2,5,6-tetrahydropyridine amide derivatives |
| 03/21/2002 | US20020035147 Nervous system, psychological disorders |
| 03/21/2002 | US20020035137 Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors |
| 03/21/2002 | US20020035136 Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors |
| 03/21/2002 | US20020035129 Cholinesterase inhibitor |
| 03/21/2002 | US20020035128 Cholinesterase inhibitors |
| 03/21/2002 | US20020035126 Side effect reduction |
| 03/21/2002 | US20020035123 For treating pain or memory deficiencies related to Alzheimer's disease and other neurodegenerative disorders associated with aging |
| 03/21/2002 | US20020035072 Method for enhancing mutant enzyme activities in lysosomal storage disorders |
| 03/21/2002 | CA2422055A1 Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| 03/21/2002 | CA2422013A1 Substituted urea neuropeptide y y5 receptor antagonists |
| 03/20/2002 | EP1188742A1 Vinylated alkoxyamine, use thereof, and process for producing the same |
| 03/20/2002 | EP1187830A1 Process for the preparation of paroxetine and structurally related compounds |
| 03/20/2002 | EP1187811A1 Inhibitors of metalloproteinases |
| 03/20/2002 | EP1187810A2 Heterocyclic analgesic compounds and their use |
| 03/20/2002 | EP0944590B1 Aminoguanidines and alkoxyguanidines as protease inhibitors |
| 03/20/2002 | EP0871446B1 Use of eliprodil for the manufacture of a medicament for the treatment of ischemic disorders of the retina or the optic nerve |
| 03/20/2002 | EP0782569B1 Racemisation process used in the manufacture of levobupivacaine and analogues thereof |
| 03/20/2002 | CN1341095A Amide compounds for potentiation of cholinergic activity |
| 03/20/2002 | CN1341094A Monoamine reuptake inhibitors for treatment of CNS disorders |
| 03/19/2002 | US6359139 Reacting 1-threo-piperidyl acetamide with an alkanoic acid in solvnet |
| 03/19/2002 | US6359138 4-hydroxy-piperidine derivatives |
| 03/19/2002 | US6359134 Sulfonamide derivatives, their production and use |
| 03/19/2002 | US6358982 Heterocyclyl sulphonamide derivatives |
| 03/19/2002 | US6358980 For therapy of arthritis, tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and hiv infection |
| 03/19/2002 | US6358979 N-cyclopentyl modulators of chemokine receptor activity |
| 03/19/2002 | US6358977 Therapy of neurodevelopmental disorder such as autistic spectrum disorders/autistic continuum disorders, pervasive developmental disorders, attention deficit hyperactivity disorder, etc., by administering piperidinemethanol compound |
| 03/19/2002 | US6358965 Use of benzoylalkyl-1,2,3,6-tetrahydropyridines |
| 03/19/2002 | US6358960 For therapy of intravascular coagulation, coronary thrombosis, cerebral infarction, cerebral embolism, transient ischemic attack, cerebrovascular disorders, pulmonary vascular diseases, deep venous thrombosis, etc. |
| 03/19/2002 | US6358504 Compounds and compositions for delivering active agents |
| 03/19/2002 | CA2084082C 1-pyperidinyl alkanoylarysulfonamide derivatives |
| 03/19/2002 | CA2032797C Antithrombotic compounds |
| 03/14/2002 | WO2002020526A2 Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents |
| 03/14/2002 | WO2002020501A2 Polyarylcarboxamides useful as lipid lowering agents |
| 03/14/2002 | WO2002020500A2 Materials and methods to potentiate cancer treatment |
| 03/14/2002 | WO2002020485A1 Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases |
| 03/14/2002 | WO2002020484A1 Chemical compounds |
| 03/14/2002 | WO2002020483A1 Piperidine derivatives for use 2,3-oxidosqualene-lanosterol cyclase inhibitors |
| 03/14/2002 | WO2001070734A3 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| 03/14/2002 | US20020032335 Manufacture of single isomer methylphenidate |
| 03/14/2002 | US20020032334 Oligomers and polymers of di-substituted cyclic imino carboxylic acids |
| 03/14/2002 | US20020032219 Use of alpha-1c specific compounds to treat benign prostatic hyperplasia |
| 03/14/2002 | US20020032186 N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
| 03/14/2002 | DE10041402A1 Neue Verbindungen, die Faktor Xa-Aktivität inhibieren Novel compounds which inhibit factor Xa activity |
| 03/14/2002 | CA2421506A1 Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents |
| 03/14/2002 | CA2417177A1 Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases |
| 03/13/2002 | EP1186304A2 Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
| 03/13/2002 | EP1185522A1 Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions containing them |
| 03/13/2002 | EP1185512A2 INHIBITORS OF FACTOR Xa |
| 03/13/2002 | EP1185511A2 Inhibitors of factor xa |
| 03/13/2002 | EP1185267A1 Dermal anesthetic agents |
| 03/13/2002 | EP1185266A1 Amorphous form of fexofenadine hydrochloride |
| 03/13/2002 | EP0876343B1 Aromatic keto-acids and their derivatives as inhibitors of matrix metalloproteinases |
| 03/13/2002 | CN1340045A 5-HTIF agonists |
| 03/13/2002 | CN1340044A Nervinolin derivatives |
| 03/12/2002 | US6355810 Multibinding inhibitors of HMG-CoA reductase |
| 03/12/2002 | US6355805 β3-adrenergic receptor agonists |
| 03/12/2002 | US6355804 Process for producing piperidinecarboxylic acid amide derivatives |
| 03/12/2002 | US6355672 Bone disorders; central nervous system disorders |
| 03/12/2002 | US6355656 Phenidate drug formulations having diminished abuse potential |
| 03/12/2002 | US6355655 Treating a cognitive disorder, a neuro-degenerative disorder; age-related dementia; age-induced memory impairment; a movement disorder, attention deficit disorder; attention deficit hyperactivity disorder; psychosis; cognitive deficits |
| 03/12/2002 | CA2060393C Carbamic acid derivatives and method for preparing the same |
| 03/12/2002 | CA2055947C Condensed heterocyclic compounds, their production and use |
| 03/07/2002 | WO2002018515A1 Liquid crystal mixture |
| 03/07/2002 | WO2002018338A1 Process for the racemisation of 1-benzyl-4-(4-fluorophenyl)-3-hydroxymethyl-1,2,3,6-tetrahydropyridine to be used as intermediate in the synthesis of paroxetine |
| 03/07/2002 | WO2002018337A1 Process for the racemisation of an intermediate useful in the preparation of paroxetine |
| 03/07/2002 | WO2002018334A2 Sodium channel modulators |
| 03/07/2002 | WO2002018323A2 Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors |
| 03/07/2002 | WO2002018321A2 Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors |
| 03/07/2002 | WO2002017919A2 Use of threo-methylphenidate compounds to enhance memory |
| 03/07/2002 | WO2002017712A2 Disubstituted benzenes as insecticides |
| 03/07/2002 | WO2001085680A3 Sulfonyl aryl or heteroaryl hydroxamic acid compounds |
| 03/07/2002 | WO2001068645A3 N-cyanomethylcarboxamides and their use as protease inhibitors |
| 03/07/2002 | US20020028944 Chemical intermediate for pharmaceuticals such as paroxetine |
| 03/07/2002 | US20020028943 For lowering serum lipid, cholesterol and/or triglyceride levels; treating atherosclerosis |
| 03/07/2002 | US20020028835 Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| 03/07/2002 | US20020028834 Heterocyclic-cyclic amine derivatives |
| 03/07/2002 | US20020028833 Aryl alkenamides derivatives as mcp-1 antagonists |
| 03/07/2002 | US20020028832 Substituted 4-((4-amino-5-hydroxyphenyl)-oxy-)piperidine analogs; metabolic disorders; antidiabetic agents; athero-sclerosis, gastrointestinal disorders, glaucoma, neurogenetic inflammation, ocular hypertension and frequent urination |
| 03/07/2002 | US20020028821 Benzyl(idene)-lactam derivatives, their preparation and their use as selective (ant)agonists of 5-ht1a- and/or 5-ht1d receptors |
| 03/07/2002 | US20020028799 Using protease and phospodiesterase inhibitor |
| 03/07/2002 | US20020028797 Therapy for metabolism diseases; dietetics; antidiabetic agents |
| 03/07/2002 | US20020028774 C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| 03/07/2002 | US20020028247 Micro-particulate form of a tetrahydropyridin derivative |
| 03/07/2002 | DE10040783A1 AZA-Aminosäurederivate (Faktor X¶a¶-Inhibitoren 15) AZA-amino acid derivatives (factor inhibitors X¶a¶ 15) |
| 03/07/2002 | CA2420569A1 Use of threo-methylphenidate compounds to enhance memory |
| 03/07/2002 | CA2416740A1 Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors |
| 03/06/2002 | EP1184442A1 Liquid crystal mixture |
| 03/06/2002 | EP1184374A1 Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorders |
| 03/06/2002 | EP1184370A2 Compounds with growth hormone releasing properties |
| 03/06/2002 | EP1184358A2 Process for treatment and purification of the reaction products obtained by reduction with lithium aluminium hydride |
| 03/06/2002 | EP1183239A1 Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
| 03/06/2002 | EP1183238A1 Metabotropic glutamate receptor antagonists |
| 03/06/2002 | EP1183233A2 Bradykinin receptor antagonists |